Update on second primary malignancies in multiple myeloma: a focused review

Area of Science:

• Hematology
• Oncology
• Clinical Medicine

Background:

• Significant advancements in multiple myeloma (MM) management have improved patient survival.
• Increased survival leads to new challenges, including the emergence of second primary malignancies (SPMs).

Purpose of the Study:

• To review current information on the mechanisms and risks of developing SPMs in MM patients.
• To focus on disease- and treatment-related factors contributing to SPM risk.

Main Methods:

• Review of three randomized studies evaluating maintenance lenalidomide in MM.
• Analysis of data regarding clinical benefits and risks of SPMs associated with lenalidomide maintenance.

Main Results:

• Maintenance lenalidomide demonstrated potential clinical benefits in MM patients.
• The same studies indicated an increased risk of second primary malignancies with lenalidomide maintenance therapy.

Conclusions:

• Improved survival in MM necessitates addressing long-term complications like SPMs.
• Understanding disease- and treatment-related factors is crucial for managing SPM risk in MM patients.